Navigation Links
Cardium Reports on Second Quarter 2008 Highlights and Financial Results

SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) today reported recent highlights and developments, as well as financial results for its second quarter ended June 30, 2008.

Highlights and Recent Developments

-- Announcement of CE mark approval and Underwriters Laboratories, Inc. (UL) certification for the new RapidBlue endovascular temperature modulation system. The CE mark will allow InnerCool to begin marketing the Rapid Blue system in Europe and many other countries that recognize the certification. InnerCool expects to begin selling the RapidBlue System through its established distribution network in the third quarter. As previously reported, InnerCool's RapidBlue System is currently completing review for FDA 510(k) clearance.

-- Ongoing patient recruitment for the Company's Phase 2b Excellarate MATRIX clinical trial. The MATRIX Study website at was developed to provide patients, caregivers and physicians with information about the study. The MATRIX clinical trial is evaluating the safety and efficacy of Excellarate for the potential treatment of non-healing diabetic foot ulcers and is expected to enroll up to approximately 210 patients at up to 40 U.S. sites. The study has also been the focus of media attention in multiple regions across the U.S. To view television video clips and newspaper articles, please visit Recruiting MATRIX clinical study sites and additional information can be found at Tissue Repair Company's website at

-- Ongoing patient recruitment of the Phase 3 Generx AWARE clinical Trial. The AWARE study website at was launched to provide information about the study to patients, caregivers and physicians. The AWARE study is evaluating the therapeutic effects of Generx for the potential treatment of myocardial ischemia (insufficient blood flow within the heart muscle) and associated angina due to coronary heart disease. Recruiting AWARE clinical study sites and additional information can be found at Cardium's website at

-- Appointment of Paul A. Foster, M.D. as Chief Medical Officer to lead the Company's MATRIX Phase 2b clinical study and the AWARE Phase 3 clinical study. Dr. Foster has held leadership clinical development and medical affairs positions at Reata Pharmaceuticals, IDEC Pharmaceuticals Corporation, Biogen Idec and Alpha Therapeutic and also has experience in the medical device arena, previously holding director positions at Abbot Laboratories and Dade Behring. Dr. Foster received his M.D. degree and medical training at Duke University.

-- Completion of two follow-on registered direct investments by institutional and other accredited investors with gross proceeds totaling approximately $6.6 million excluding placement agent fees and offering expenses and excluding any future proceeds from the exercise of the warrants issued in the offerings.

Financial Report

For the quarter ended June 30, 2008, the Company reported a net loss of $6.6 million, or $0.15 per share, which included research and development costs totaling $4.0 million and selling, general and administrative expenses of $2.7 million. Non-cash charges relating to stock-based compensation, depreciation and amortization for the second quarter of fiscal 2008 totaled $943,000. Total revenue for the second quarter 2008 was $627,000, compared to $229,000 for the same quarter last year. The increase in revenue was a result of an increase in InnerCool sales resulting from our expanded sales and marketing efforts and an increase in the level of activity on the grant at our subsidiary Tissue Repair Company. Cash and cash equivalents as of June 30, 2008 were $4.1 million. In July 2008, the Company used $3.1 million to pay off the principal balance on its commercial credit facility, thereby retiring its remaining debt obligations to Life Sciences Capital; and completed a registered direct investment resulting in gross proceeds of approximately $3.34 million, before placement agent fees and offering expenses and excluding any future proceeds from the exercise of the warrants issued in the offering.

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit or view its 2007 Annual Report at

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's Celsius Control System(TM) and its CoolBlue(TM) System, please visit

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that human clinical trials can be conducted and completed in an efficient and successful manner, that product modifications or launches will be successful or that the resulting products will be favorably received in the marketplace, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that our products or product candidates will prove to be sufficiently safe and effective, that necessary regulatory approvals will be obtained, that third parties on whom we depend will perform as anticipated, or that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and therapeutic hypothermia devices and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our ability to successfully accelerate the commercialization of our therapeutic hypothermia devices and launch new devices within the timeframes contemplated, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward- looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2008 Cardium Therapeutics, Inc. All rights reserved.

For Terms of Use Privacy Policy, please visit

Cardium Therapeutics(TM), Corgentin(TM) and Generx(TM) are trademarks of
Cardium Therapeutics, Inc. Tissue Repair(TM), Gene Activated Matrix(TM), GAM(TM) and Excellarate(TM) are
trademarks of the Tissue Repair Company.

InnerCool Therapies(R), InnerCool(R), Celsius Control System(TM), Accutrol(TM), CoolBlue(TM) and RapidBlue(TM)are trademarks of InnerCool

Therapies, Inc.

Cardium Therapeutics, Inc.

Three Months Ended

June 30,


Selected Condensed Consolidated 2008 2007

Operational Results

Revenues $626,841 $229,472

Cost of goods sold (314,254) (258,177)

Gross profit (loss) 312,587 (28,705)

Research and development 3,969,406 3,415,213

Selling, general and administrative 2,696,559 2,978,448

Amortization - Intangibles 197,414 207,043

Loss from operations (6,550,792) (6,629,409)

Interest income (expense), net (83,670) 228,228

Net loss $(6,634,462) $(6,401,181)

Net loss per common

share - basic and diluted $(0.15) $(0.16)

Weighted average common shares

outstanding - basic and diluted 43,629,975 40,914,902

Selected Condensed Consolidated June 30, December 31,

Balance Sheet Data 2008 2007

(Unaudited) (Audited)

Cash and cash equivalents $4,138,989 $7,722,816

Accounts receivable, net 406,963 565,613

Inventories, net 1,741,439 1,037,164

Prepaid expenses and other current assets 537,124 522,067

Property and equipment, net 2,006,735 1,650,632

Patented technology and

intangibles, net 4,371,502 4,766,330

Other long-term assets 600,041 661,067

Total assets $13,802,793 $16,925,689

Current liabilities $9,602,428 $5,255,392

Long-term liabilities 96,420 3,241,992

Stockholder's equity 4,103,945 8,428,305

Total liabilities and

stockholder's equity $13,802,793 $16,925,689

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
4. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
7. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
10. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
11. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Post Your Comments:
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in agile ... a contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise ... use of Agile methodologies in a consistent and high value manner across CMS ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
Breaking Medicine News(10 mins):